pretreatment

Original Contribution

Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients

07/15/2018

Benoit Lattuca, MD¹; David Belardi, MD¹; Christophe Demattei, MD²; Laurent Schmutz, MD¹; Luc Cornillet, MD¹; Bertrand Ledermann, MD¹; Jean-Christophe Macia, MD³; Ana√Øs Iemmi, MD³; Richard Gervasoni, MD³; Fran√ßois Roubille, MD, PhD³; Thien Tri Cung, MD³; Pierre Robert, MD³; Patrick Messner-Pellenc, MD, PhD¹; Florence Leclercq, MD, PhD³; Guillaume Cayla, MD, PhD¹

Benoit Lattuca, MD1; David Belardi, ...

Recent studies have challenged systematic pretreatment with a P2Y12 inhibitor before PCI in elective and NSTEMI patients. This study assesses outcomes after performing PCI immediately after coronary angiography with an exclusive...

Recent studies have challenged...

07/15/2018

Journal of Invasive Cardiology

Original Contribution

Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

04/15/2017

Devraj Sukul, MD¹; Milan Seth, MS¹; Simon R. Dixon, MBChB²; Akshay Khandelwal, MD³; Thomas A. LaLonde, MD⁴; Hitinder S. Gurm, MD^1,5

Devraj Sukul, MD1; Milan Seth, MS1; ...

We sought to describe trends in the use of preprocedural P2Y12 inhibitors and their clinical impact in patients undergoing percutaneous coronary intervention (PCI).

We sought to describe trends in...

04/15/2017

Journal of Invasive Cardiology